Darwin Global Management, Ltd.
Long book
$3.77B
Q1 2026
Positions
6
Top-10 weight
100%
concentration
Last quarter
-13.5%
SPY +14.8%
Turnover
67%
of book per quarter
Strategy in plain words
auto-generated from filingsDarwin Global Management, Ltd. is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $3.77B US long book across 6 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: INSMED INC, BELITE BIO INC - ADR, ABIVAX SA-ADR, REVOLUTION MEDICINES INC, ROIVANT SCIENCES LTD.
Over the last 9 quarters its long book ran on average 2.8pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-14.1%
Q2 2024
+14.2%
Q3 2024
-16.6%
Q4 2024
+6.4%
Q1 2025
+31.2%
Q2 2025
+42.9%
Q3 2025
+22.8%
Q4 2025
-7.8%
Q1 2026
-13.5%
Sector allocation
Healthcare 100%
Long book by quarter
What does Darwin Global own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 6 | $3.77B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 6 | $4.94B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 5 | $3.60B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 5 | $2.38B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 3 | $1.46B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 6 | $1.06B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 5 | $1.23B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 9 | $859.5M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 12 | $751.2M | canonical | SEC ↗ |